Introduction: Multimorbidity, defined as the presence of two or more chronic conditions, is associated with poor outcomes and increased cardiovascular risk in the general population. However, the effect of multimorbidity on patients with chronic kidney disease (CKD), a group of patients already at high risk for cardiovascular disease, is not well understood. Methods: We analyzed data from 4,420 patients with non-dialysis CKD enrolled in the Fukuoka Kidney disease Registry Study. We identified 23 comorbidities, including cardiometabolic and non-cardiometabolic conditions. The patients were categorized into four groups according to the number of comorbidities: Group 1 (0–1 comorbidities), Group 2 (2 comorbidities), Group 3 (3 comorbidities), and Group 4 (≥4 comorbidities). We examined the associations between the number of comorbidities and the incidence of major adverse cardiovascular events (MACE) and all-cause mortality using Cox proportional hazards models. Results: Over a 5-year follow-up, 229 patients experienced MACE and 456 died. The risk of MACE increased with the number of comorbidities. The multivariable-adjusted hazard ratios (95% confidence intervals) for MACE were 1.40 (0.80–2.44) for Group 2, 2.27 (1.33–3.88) for Group 3, and 3.53 (2.11–5.91) for Group 4 compared with Group 1. The all-cause mortality risk also increased with the number of comorbidities, with adjusted hazard ratios of 1.13 (0.77–1.66), 1.75 (1.22–2.51), and 2.53 (1.80–3.54) for Groups 2, 3, and 4, respectively. Conclusion: In patients with CKD, multimorbidity is associated with an increased risk of MACE and all-cause mortality.

1.
Chapter 1: definition and classification of CKD
.
Kidney Int Suppl
.
2013
;
3
(
1
):
19
62
.
2.
Jankowski
J
,
Floege
J
,
Fliser
D
,
Böhm
M
,
Marx
N
.
Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options
.
Circulation
.
2021
;
143
(
11
):
1157
72
.
3.
Go
AS
,
Chertow
GM
,
Fan
D
,
McCulloch
CE
,
Hsu
C-Y
.
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
.
N Engl J Med
.
2004
;
351
(
13
):
1296
305
.
4.
Pagels
AA
,
Söderkvist
BK
,
Medin
C
,
Hylander
B
,
Heiwe
S
.
Health-related quality of life in different stages of chronic kidney disease and at initiation of dialysis treatment
.
Health Qual Life Outcomes
.
2012
;
10
:
71
.
5.
O’Hare
AM
,
Choi
AI
,
Bertenthal
D
,
Bacchetti
P
,
Garg
AX
,
Kaufman
JS
, et al
.
Age affects outcomes in chronic kidney disease
.
J Am Soc Nephrol
.
2007
;
18
(
10
):
2758
65
.
6.
Astor
BC
,
Matsushita
K
,
Gansevoort
RT
,
van der Velde
M
,
Woodward
M
,
Levey
AS
, et al
.
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts
.
Kidney Int
.
2011
;
79
(
12
):
1331
40
.
7.
Ritchie
J
,
Rainone
F
,
Green
D
,
Alderson
H
,
Chiu
D
,
Middleton
R
, et al
.
Extreme elevations in blood pressure and all-cause mortality in a referred CKD population: results from the CRISIS study
.
Int J Hypertens
.
2013
;
2013
:
597906
.
8.
Nakamura
K
,
Nakagawa
H
,
Murakami
Y
,
Kitamura
A
,
Kiyama
M
,
Sakata
K
, et al
.
Smoking increases the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease
.
Kidney Int
.
2015
;
88
(
5
):
1144
52
.
9.
Skou
ST
,
Mair
FS
,
Fortin
M
,
Guthrie
B
,
Nunes
BP
,
Miranda
JJ
, et al
.
Multimorbidity
.
Nat Rev Dis Primers
.
2022
;
8
(
1
):
48
.
10.
Ali
MM
,
Parveen
S
,
Williams
V
,
Dons
R
,
Uwaifo
GI
.
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)
.
J Clin Transl Endocrinol
.
2024
;
36
(
100341
):
100341
.
11.
Zemplényi
A
,
Sághy
E
,
Kónyi
A
,
Szabó
L
,
Wittmann
I
,
Laczy
B
.
Prevalence, cardiometabolic comorbidities and reporting of chronic kidney disease; a Hungarian cohort analysis
.
Int J Public Health
.
2023
;
68
:
1605635
.
12.
Nicholson
K
,
Liu
W
,
Fitzpatrick
D
,
Hardacre
KA
,
Roberts
S
,
Salerno
J
, et al
.
Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review
.
Lancet Healthy Longev
.
2024
;
5
(
4
):
e287
96
.
13.
Gebreyohannes
EA
,
Gebresillassie
BM
,
Mulugeta
F
,
Dessu
E
,
Abebe
TB
.
Treatment burden and health-related quality of life of patients with multimorbidity: a cross-sectional study
.
Qual Life Res
.
2023
;
32
(
11
):
3269
77
.
14.
Hanlon
P
,
Jani
BD
,
Nicholl
B
,
Lewsey
J
,
McAllister
DA
,
Mair
FS
.
Associations between multimorbidity and adverse health outcomes in UK Biobank and the SAIL Databank: a comparison of longitudinal cohort studies
.
PLoS Med
.
2022
;
19
(
3
):
e1003931
.
15.
Hirst
JA
,
Ordóñez Mena
JM
,
O’Callaghan
CA
,
Ogburn
E
,
Taylor
CJ
,
Yang
Y
, et al
.
Prevalence and factors associated with multimorbidity among primary care patients with decreased renal function
.
PLoS One
.
2021
;
16
(
1
):
e0245131
.
16.
Tanaka
S
,
Ninomiya
T
,
Fujisaki
K
,
Yoshida
H
,
Nagata
M
,
Masutani
K
, et al
.
The Fukuoka kidney disease registry (FKR) study: design and methods
.
Clin Exp Nephrol
.
2017
;
21
(
3
):
465
73
.
17.
Schwartz
GJ
,
Haycock
GB
,
Edelmann
CM
Jr
,
Spitzer
A
.
A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine
.
Pediatrics
.
1976
;
58
(
2
):
259
63
.
18.
Schwartz
GJ
,
Brion
LP
,
Spitzer
A
.
The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents
.
Pediatr Clin North Am
.
1987
;
34
(
3
):
571
90
.
19.
Matsuo
S
,
Imai
E
,
Horio
M
,
Yasuda
Y
,
Tomita
K
,
Nitta
K
, et al
.
Revised equations for estimated GFR from serum creatinine in Japan
.
Am J Kidney Dis
.
2009
;
53
(
6
):
982
92
.
20.
Tanaka
S
,
Nakano
T
,
Hiyamuta
H
,
Tsuruya
K
,
Kitazono
T
.
Association between multimorbidity and kidney function among patients with non-dialysis-dependent CKD: the Fukuoka kidney disease registry study
.
J Atheroscler Thromb
.
2022
;
29
(
8
):
1249
64
.
21.
Muntner
P
,
Anderson
A
,
Charleston
J
,
Chen
Z
,
Ford
V
,
Makos
G
, et al
.
Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) study
.
Am J Kidney Dis
.
2010
;
55
(
3
):
441
51
.
22.
Araki
E
,
Goto
A
,
Kondo
T
,
Noda
M
,
Noto
H
,
Origasa
H
, et al
.
Japanese clinical practice guideline for diabetes 2019
.
Diabetol Int
.
2020
;
11
(
4
):
1020
76
.
23.
Balan
TA
,
Putter
H
.
A tutorial on frailty models
.
Stat Methods Med Res
.
2020
;
29
(
11
):
3424
54
.
24.
Whelton
PK
,
Carey
RM
,
Aronow
WS
,
Casey
DE
Jr
,
Collins
KJ
,
Dennison Himmelfarb
C
, et al
.
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines
.
Hypertension
.
2018
;
71
(
6
):
e13
15
.
25.
Janssen
KJM
,
Donders
ART
,
Harrell
FE
Jr
,
Vergouwe
Y
,
Chen
Q
,
Grobbee
DE
, et al
.
Missing covariate data in medical research: to impute is better than to ignore
.
J Clin Epidemiol
.
2010
;
63
(
7
):
721
7
.
26.
Tonelli
M
,
Wiebe
N
,
Guthrie
B
,
James
MT
,
Quan
H
,
Fortin
M
, et al
.
Comorbidity as a driver of adverse outcomes in people with chronic kidney disease
.
Kidney Int
.
2015
;
88
(
4
):
859
66
.
27.
Ritchie
C
,
Ekundayo
OJ
,
Muchimba
M
,
Campbell
RC
,
Frank
SJ
,
Liu
B
, et al
.
Effects of diabetes mellitus in patients with heart failure and chronic kidney disease: a propensity-matched study of multimorbidity in chronic heart failure
.
Int J Cardiol
.
2009
;
134
(
3
):
330
5
.
28.
Ndumele
CE
,
Rangaswami
J
,
Chow
SL
,
Neeland
IJ
,
Tuttle
KR
,
Khan
SS
, et al
.
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
.
Circulation
.
2023
;
148
(
20
):
1606
35
.
29.
Aksentijevich
M
,
Lateef
SS
,
Anzenberg
P
,
Dey
AK
,
Mehta
NN
.
Chronic inflammation, cardiometabolic diseases and effects of treatment: psoriasis as a human model
.
Trends Cardiovasc Med
.
2020
;
30
(
8
):
472
8
.
30.
Cooper
BA
,
Penne
EL
,
Bartlett
LH
,
Pollock
CA
.
Protein malnutrition and hypoalbuminemia as predictors of vascular events and mortality in ESRD
.
Am J Kidney Dis
.
2004
;
43
(
1
):
61
6
.
31.
Tang
Z
,
Wang
C
,
Song
X
,
Shi
J
,
Mitnitski
A
,
Fang
X
, et al
.
Co-occurrence of cardiometabolic diseases and frailty in older Chinese adults in the Beijing Longitudinal Study of Ageing
.
Age Ageing
.
2013
;
42
(
3
):
346
51
.
32.
Nolin
TD
.
A synopsis of clinical pharmacokinetic alterations in advanced CKD
.
Semin Dial
.
2015
;
28
(
4
):
325
9
.
You do not currently have access to this content.